Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Tumor antigen Stories

2008-10-22 12:00:20

ERYtech Pharma, a French biotechnology company, will present very promising results from its original approach on antitumor vaccination at the 6th International Cancer Vaccine Symposium to be held in New York from October 28-30, 2008. These results, obtained from animal studies confirm that the Vaccin'ERY(TM) system is efficient. This technology, patented by ERYtech Pharma, is very unique. It consists in using tumor antigens loaded red blood cells to specifically target and activate...

2008-10-10 09:00:52

ImmunoCellular Therapeutics, a biotechnology company, has filed a provisional US patent application relating to its vaccine technology targeting cancer stem cells. The vaccine technology is exclusively licensed from Cedars-Sinai Medical Center. The patent claims are broad and include compositions of peptides for cancer immunotherapy as well as methods for inducing immune responses against tumor antigens in cancer patients. The vaccine being developed by ImmunoCellular Therapeutics (IMUC)...

2008-09-23 06:00:32

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today announces a collaborative relationship with the University of North Carolina at Charlotte to evaluate ImmuneRegen's Viprovex as a possible cancer-vaccine adjuvant. Adjuvants are agents that stimulate and, subsequently, augment the immune system's response to a foreign antigen. The studies will be under the direction of Pinku Mukherjee, Ph.D., an accomplished cellular immunologist...

2008-06-25 09:02:27

By Akins, Elizabeth J Dubey, Purnima Cell-mediated therapy (immunotherapy) for the treatment of cancer is an active area of investigation in animal models and clinical trials. Despite many advances, objective responses to immunotherapy are observed in a small number of cases, for certain tumor types. To better understand differences in outcomes, it is critical to develop assays for tracking effector cell localization and function in situ. The fairly recent use of molecular imaging...

2008-06-18 18:00:00

SEATTLE, June 18 /PRNewswire/ -- Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine. Yee and colleagues removed CD4+ T cells, a type of white...

f31024cec860b742e4a5e28841dee4fb1
2008-04-21 10:25:00

A new fundamental mechanism of how tumor cells communicate has just been discovered by the team of Dr. Janusz Rak at the Research Institute of the McGill University Health Centre (MUHC) in collaboration with Dr Guha from the University of Toronto. The cancer cells are able to communicate with their more healthy counter-parts by releasing vesicles. These bubble-like structures contain cancer-causing (oncogenic) proteins that can trigger specific mechanisms when they merge into non or...

754107b0ef594bb653035600bc490a62
2008-03-03 10:25:00

Researchers find way to regulate immune inhibitor to overcome tumor supressionResearchers at the University of Southern California (USC) have uncovered a new way to develop more effective tumor vaccines by turning off the suppression function of regulatory T cells. The results of the study, titled "A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression," was published in Nature Medicine on March 2, 2008."Under normal circumstances,...

2005-08-10 15:50:00

Bethesda, MD "“ Researchers have discovered that tumors release fatty acids that interfere with the cells that are trying to kill them. Consequently, strategies that reduce the amount of fatty acids surrounding the tumors may give a boost to anti-cancer therapeutics. The details of these findings appear in the September issue of the Journal of Lipid Research, an American Society for Biochemistry and Molecular Biology journal. Several forms of anti-cancer therapy rely on what is known...

2005-06-13 15:50:33

LOS ANGELES (June 13, 2005) - In the August issue of the journal Oncogene, researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute describe a molecular mechanism that appears to make malignant brain tumors more vulnerable to chemotherapy after they have been treated with the dendritic cell vaccine. This finding builds on several studies recently published by the research team. In 2003, they reported that a protein fragment previously found in melanomas also was...